About this paper
Should life science companies be expected to share patient-level data from their clinical trials? Groups such as the European Medicines Agency and the AllTrials campaign say yes; it's in the public interest to do so. Forward-thinking companies are taking bold steps toward data sharing because it's also good business and good science. This article summarizes discussion on the topic with industry leaders at the Clinical Trial Data Transparency Forum, sponsored by SAS, held in October 2013.
SAS는 분석 부문의 선두 기업입니다. SAS의 혁신적인 소프트웨어와 서비스는 전세계 고객사가 데이터를 기반으로 인텔리전스를 극대화할 수 있도록 지원합니다. SAS는 THE POWER TO KNOW®를 실현합니다.